Evidence base
Registered on ClinicalTrials
Results of an international multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of sequential therapy with ethylmethylhydroxypyridine succinate in patients in the acute and early recovery periods of ischemic stroke (IS)
Registered on ClinicalTrials
N.A. SHAMALOV1, A.I. FEDIN2, G.S. RAKHIMBAYEVA3, E.S. NURGUZHAEV4, D.R. KHASANOVA5, E.Yu. SOLOVIOVA2, E.V. MELNIKOVA6, S.N. YANISHEVSKY7, V.V. MASHIN8, N.V. PIZOVA9, I.E. Poverennova10, S.E. CHUPRINA11, A.S. AGAFINA12, L.V. ROSHKOVSKA13
1Federal Center for Brain and Neurotechnology of the Federal Medical and Biological Agency of the Russian Federation, Moscow, Russia;
2Pirogov Russian National Research Medical University, Moscow, Russia;
3Tashkent Medical Academy, Tashkent, Uzbekistan;
4Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan;
5Kazan State Medical University, Kazan, Russia;
6Leningrad Regional Center for Medical Rehabilitation, Kommunar, Russia;
7Almazov National Medical Research Center, Saint Petersburg, Russia;
8Ulyanovsk State University, Ulyanovsk, Russia;
9Yaroslavl State Medical University, Yaroslavl, Russia.
10.Samara Regional Clinical Hospital named after V.D. Seredavin, Samara, Russia;
11.Voronezh Regional Clinical Hospital No. 1, Voronezh, Russia;
12.St. Petersburg City Hospital No. 40, St. Petersburg, Russia;
13.St. Petersburg Alexandrovskaya Hospital, St. Petersburg, Russia
Place of publication:
S.S. Korsakov Journal of Neurology and Psychiatry 2025, Vol. 125, No. 8, Issue 2, pp. 40–53
https://doi.org/10.17116/jnevro202512508240
International multicenteric randomized double-tied placebo-controlled study of evaluating the effectiveness and safety of sequential therapy of patients with chronic brain ischemia drugs Mexidol® and Mexidol® Forte 250 (study of memo): Subanalysis results in patients with arterial hypertension
V.V. ZAKHAROV1, O.D. OSTROUMOVA1,2, A.I. KOCHETKOV2, M.V. KLEPIKOVA2, A.I. FEDIN3
1Federal State Autonomous Educational Institution of Higher Education “I.M. Sechenov First Moscow State Medical University” of the Russian Ministry of Health (Sechenov University);
2Federal State Budgetary Educational Institution of Higher Professional Education “Russian Medical Academy of Continuous Professional Education” of the Russian Ministry of Health, Moscow;
3Federal State Autonomous Educational Institution of Higher Education “N.I. Pirogov Russian National Research Medical University” of the Russian Ministry of Health, Moscow
Place of publication:
THERAPY No. 1 (63) 2023
To the question of the evidence base of neuroprotective therapy: Focus on ethylmethylhydroxypyridine succinate
Authors:
A.I. KOCHETKOV, N.A. SHATALOVA, M.V. KLEPIKOVA, T.V. FILIPPOVA, O.D. OSTROUMOVA
Federal State Budgetary Educational Institution of Higher Professional Education “Russian Medical Academy of Continuous Professional Education” of the Ministry of Health of the Russian Federation, Moscow
The effectiveness of Mexidol in patients of different age groups with chronic brain ischemia with cognitive disorders (the results of subanalysis of the international multicenter randomized double blind placebo-controlled study of memes)
Zakharov V.V. 1*, Tkacheva O.N. 2*, 3*, Mkhitaryan E.A. 2*, 3*, Fedin A.I. 2*
1* I.M. Sechenov First Moscow State Medical University of the Russian Ministry of Healthcare
(Sechenov University), Moscow, Russia;
2* N.I. Pirogov Russian National Research Medical University of the Russian Ministry of Healthcare,
Moscow, Russia;
3* Russian Gerontology Research and Clinical Center of N.I. Pirogov Russian National Research
Medical University of the Russian Ministry of Healthcare, Moscow, Russia
Place of publication:
S.S. Korsakov Journal of Neurology and Psychiatry
2022, Vol. 122, No. 11, Issue 2, pp. 73–80
Promising Effects of Emoxypine and Its Succinate Derivate in the Management of Various Disess-Withs on Recent Patent Applications
Dhruv Sanjay Gupta, Siddhi Bagwe Parab, Ginpreet Kaur
Translated from Zhurnal Nevrologii i Psikhiatrii imeni SS Korsakova, Vol. 121, No. 12, Iss. 2, pp. 69–76,
December, 2021. Original article submitted December 20, 2021. Accepted December 22, 2021.
Publication location:
Neuroscience and Behavioral Physiology, Vol. 52, No. 5, June 2022
The results of an international multicenter randomized double-blind-controlled study of evaluating the effectiveness of the effectiveness and safety of consistent therapy of patients with chronic brain ischemia with Mexidol and Mexidol Forte 250 (study of Memo)
Registered on ClinicalTrials
A.I. FEDIN1, V.V. ZAKHAROV2, M.M. TANASHYAN3, E.I. CHUKANOVA1, E.N. MAJIDOVA4, L.A. SCHEPANKEVICH5.6, O.D. OSTROUMOVA7
1Pirogov Russian National Research Medical University, Moscow, Russia;
2I.M. Sechenov First Moscow Medical University,
3Neurology Research Center,
4, Russia;
5Novosibirsk State Medical University, Novosibirsk
6Federal Research Center for Fundamental and Translational Medicine, Novosibirsk, Russia;
7Russian Medical Academy of Continuous Professional Education, Moscow, Russia
Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2021, Vol. 121, No. 11
Original and reproduced drugs: what do the clinician need to know?
Author:
A.V. SHCHULKIN, A.A. FILIMONOVA
Federal State Budgetary Educational Institution of Higher Education “Ryazan State Medical University” of the Ministry of Health of the Russian Federation, Ryazan, Russia
Reproduced drugs: Benefit ratio/risk
E.A. USHKALOVA1, S.K. ZYRYANOV1,2, I.A. GOPIENKO1
1Peoples’ Friendship University of Russia, Moscow;
2City Clinical Hospital No. 24 of the Moscow Department of Health, Moscow
Pharmacoeconomic analysis of neuroprotectors used in the treatment of ischemic stroke
Authors:
R.I. YAGUDINA1, A.Yu. KULIKOV1, V.A. KRYLOV1, E.Yu. SOLOVYEVA2, A.I. FEDIN2
1Federal State Budgetary Institution of Higher Education “I.M. Sechenov First Moscow State Medical University” of the Russian Ministry of Health (Sechenov University), Moscow, Russia;
2Federal State Budgetary Institution of Higher Education “N.I. Pirogov Russian National Research Medical University” of the Russian Ministry of Health, Moscow, Russia
Modern ideas about the antihypoxic and antioxidant effects of Mexidol
Author:
A.V. SHCHULKIN
Results of a Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Effi Cace and Safety of Mexidol in Prolonged Sequential Therapy of Patient S in the Acute and Early Recovery Stages of Hemisphereic Stroke (The Epica Study)
Authors:
LV Stakhovskaya1, NA Shamalov1, DR Khasanova2, EV Melnikova3, AS Agafina4, KV Golikov5, EI Bogdanov6, AA Yakupova6, LV Roshkovskaya7, LV Lukinykh8, TM Lokshtanova9, IE Poverennova10, LA Shchepankevich11
1ResearchInstitute of Cerebrovascular Pathology and Stroke, Pirogov Russian National Research Medical University, Russian Ministry of Health, Moscow, Russia.
2Interregional Clinical Diagnostic Center, Kazan, Russia.
3St. Petersburg City Clinical Hospital No. 26, St. Petersburg, Russia.
4St. Petersburg City Clinical Hospital No. 40 of the Resort Administrative District, St. Petersburg, Russia.
5St. Petersburg City General Hospital No. 2, St. Petersburg, Russia.
6Kazan Sate Medical University, Russian Ministry of Health, Kazan, Russia.
7Nikolaevskaya Hospital, St. Petersburg, Russia.
8Vsevolzhsk Clinical Interregional Hospital, Leningradskaya Oblast, Russia.
9Pirogov City Clinical Hospital No. 1, Samara, Russia.
10Seredavin Samara Regional Clinical Hospital, Samara, Russia.
11Research Institute of Experimental and Clinical Medicine, Novosibirsk, Russia.
Publication place:
NEUROSCIENCE AND BEHAVIORAL PHYSIOLOGY, VOL. 48, NO. 8, OCTOBER, 2018
The results of a randomized double blind multicenter placebo-controlled in parallel groups of the study and safety of Mexidol with prolonged consistent therapy in patients in the acute and early recovery periods
Registered on ClinicalTrials
L.V. STAKHOVSKAYA1, N.A. SHAMALOV1, D.R. KHASANOVA2, E.V. MELNIKOVA3, A.S. AGAFINA4, K.V. GOLIKOV5, E.I. BOGDANOV6, A.A. YAKUPOVA6, L.V. ROSHKOVSKA7, L.V. LUKINYKH8, T.M. LOKSHTANOVA9, I.E. Poverennova10, L.A. SCHEPANKEVICH11
1Research Institute of Cerebrovascular Pathology and Stroke, N.I. Pirogov Russian National Research Medical University, Moscow, Russia;
2Interregional Clinical and Diagnostic Center, Kazan, Russia;
3St. Petersburg City Hospital No. 26, St. Petersburg, Russia;
4St. Petersburg City Hospital No. 40 of the Kurortny Administrative District, St. Petersburg, Russia;
5St. Petersburg City Multidisciplinary Hospital No. 2, St. Petersburg, Russia;
6Kazan State Medical University, Kazan, Russia;
7St. Petersburg Nikolaevskaya Hospital, St. Petersburg, Russia;
8Vsevolozhsk Clinical Interdistrict Hospital, Leningrad Region, Russia.
9MUBZ City Clinical Hospital No. 1 named after N.I. Pirogov, Samara, Russia;
10State Budgetary Healthcare Institution Samara Regional Clinical Hospital named after V.D. Seredavin, Samara, Russia;
11Federal State Budgetary Scientific Institution Research Institute of Experimental and Clinical Medicine, Novosibirsk, Russia.
Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2017, No. 3, ISSUE 2
THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.
Source of photos and images Shutterstock.com